Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

ESMO open·2026
Same author

Corrigendum to "First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report" [Leukemia Research Reports (2024) Volume 22, 100491].

Leukemia research reports·2025
Same author

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.

ESMO open·2025
Same author

First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report.

Leukemia research reports·2024
Same author

Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.

Cancer medicine·2024
Same author

Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.

Bone marrow transplantation·2024

Related Experiment Video

Updated: Jul 4, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Is alpha-interferon treatment in multiple myeloma worthwhile?

G Avvisati1, M T Petrucci

  • 1Department of Human Biopathology, University la Sapienza, Rome, Italy.

Stem Cells (Dayton, Ohio)
|August 1, 1995
PubMed
Summary

Alpha interferon (alpha IFN) shows promise in managing myelomatosis, particularly when combined with standard treatments for multiple myeloma. Maintenance therapy with alpha IFN may extend response and survival durations, especially after achieving a stable disease phase.

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jul 4, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Multiple myeloma (MM) is a hematologic malignancy.
  • Therapeutic options for MM are continuously evolving.
  • Alpha interferon (alpha IFN) has been investigated for its anti-cancer properties.

Purpose of the Study:

  • To review the therapeutic efficacy of alpha interferon (alpha IFN) in managing myelomatosis.
  • To evaluate the role of alpha IFN in different treatment settings for multiple myeloma.

Main Methods:

  • Literature review of studies on alpha interferon in myelomatosis.
  • Analysis of data on alpha IFN in combination with induction therapies.
  • Assessment of alpha IFN as a standalone treatment and maintenance therapy.

Main Results:

  • Alpha IFN combined with induction therapies may improve response rates in previously untreated multiple myeloma (MM) patients.
  • Alpha IFN alone can induce objective responses in some MM patients but is less effective than chemotherapy.
  • Alpha IFN maintenance therapy shows promise, particularly after achieving a stable disease phase or transplantation.

Conclusions:

  • Alpha interferon is a useful agent in myelomatosis management.
  • Combination therapy and maintenance strategies involving alpha IFN warrant further investigation.
  • Achieving a stable disease phase is crucial for maximizing the benefits of alpha IFN therapy.